Forensic Review Reveals Undisclosed Deaths and Data Discrepancies in Pfizer COVID-19 Vaccine Trial
核心洞察
Researchers conducted a forensic review of 38 deaths during the first 6-month period of Pfizer's COVID-19 (搜索) mRNA vaccine clinical trial, revealing that regulators were not informed of two deaths of vaccinated subjects.
The analysis uncovered data discrepancies that concealed a 3.7-fold increase in cardiac events among BNT162b2 vaccine recipients compared to placebo subjects.
Authors argue that accurate reporting to the FDA's Advisory Committee would have demonstrated that the vaccine did not save lives during the trial period.
A forensic analysis of deaths occurring during Pfizer's COVID-19 (搜索) mRNA vaccine clinical trial has revealed significant data discrepancies and undisclosed adverse events that may have influenced regulatory approval decisions. The findings, published in the winter issue of the Journal of American Physicians and Surgeons, raise questions about the transparency and adequacy of safety reporting during the vaccine's emergency authorization process.
Undisclosed Deaths and Reporting Delays
Researchers Jeyanthi Kunadhasen, M.D., and Corinne A. Michels, Ph.D., conducted a comprehensive review of the 38 subject deaths that occurred during the first 6-month period of the Pfizer COVID-19 mRNA vaccine (搜索) clinical trial. Their analysis revealed that regulators were not informed of two deaths of vaccinated subjects that occurred during the reporting period.
The authors identified one particularly concerning case where a subject possibly had an autopsy report of "sudden cardiac death (搜索)" that could have been made available at the critical junction prior to approval. According to the researchers, these reporting delays and other data discrepancies meant that "had accurate results been presented to the FDA's Advisory Committee, it would have been clear that the vaccine did not save lives."
Cardiac Safety Signal Concealed
The forensic review uncovered what the authors describe as "misrepresentations and obfuscations that hid a 3.7-fold increase in cardiac events in subjects who received the BNT162b2 vaccine versus the placebo." This finding suggests that cardiac safety signals were present in the trial data but were not adequately communicated to regulatory authorities.
The significance of this concealed cardiac risk became apparent later when the FDA and CDC (搜索) eventually reported "suggested increased risks" of myocarditis (搜索) and pericarditis (搜索), leading to changes in safety labels. However, by that time, thousands of teenagers had already been vaccinated. The authors note that "shamefully, the danger was minimized by telling parents that the heart damage was 'temporary.'"
Abbreviated Trial Timeline Under Emergency Provisions
The vaccines received Emergency Use Authorization in December 2020 after only 20 weeks of testing, which the authors characterize as an "artificially foreshortened" trial period. This highly atypical trial protocol was implemented under the framework of a "declared health emergency," as defined by the 2005 US PREP (Public Readiness and Emergency Preparedness) Act.
The researchers emphasize that information crucial for establishing accurate timelines remains withheld, hampering efforts to fully understand the trial's safety profile and the timing of adverse events.
Regulatory Reform Recommendations
The authors conclude that restoring public trust in regulatory agencies requires significant policy changes. They identify fundamental weaknesses in the FDA's clinical review process, particularly in the context of COVID-19 (搜索) vaccine emergency "countermeasures."
"Repeal of the PREP Act is the only way to ensure that an inadequately tested treatment of any kind will not be foisted on an unsuspecting population ever again," the authors state, calling for structural changes to prevent similar situations in future health emergencies.
The findings add to ongoing discussions about the balance between emergency medical interventions and thorough safety evaluation, particularly regarding the transparency of clinical trial data and the adequacy of regulatory oversight during public health emergencies.